Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Feb 02, 2019 6:32pm

139 Views

Post# 29310868

RE:RE:RE:RE:RE:RE:RE:SeekingAlpha.com report now available to all

Yes, that makes sense to me.

I’m sure the author made an error due to using too many abbreviations. In many ways, it often seems clearer to write out the entire term.....helps avoid errors.

That being said, I still think the theory is sound and evidently Grinspoon did as well.

bfw

jfm1330 wrote: Egrifta is a GRF analog, Tesamorelin, so it's not stimulating secretion of endogenous GRF, it is stimulating secretion of growth hormone. GRF, also called GHRH, is a 44 amino acid peptide secreted by the hypothalamus, while growth hormone is a 191 amino acids protein secreted by the anterior ptuitary gland in the brain. GRF means growth hormone releasing factor, the synonym, GHRH means growth hormone releasing hormone. I hope it's clear.

bfw wrote: Can you clarify what you think they got wrong?

I believe the author is simply extending the discussion to IGF1 due to NASH associations.

I’m pretty sure the author has a good understanding on how Egrifta works.

bfw